Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
Hong Kong
· Delayed Price · Currency is HKD 26.68
-0.56 (-2.06%)
Apr 29, 2026, 4:08 PM HKT
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 2,903 employees as of December 31, 2025. The number of employees increased by 325 or 12.61% compared to the previous year.
Employees
2,903
Change (1Y)
325
Growth (1Y)
12.61%
Revenue / Employee
957.72K HKD
Profits / Employee
-335.48K HKD
Market Cap
42.34B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Biocytogen Pharmaceuticals (Beijing) | 1,443 |
| Shanghai Henlius Biotech | 3,762 |
| 3SBio | 6,109 |
| Genscript Biotech | 6,165 |
| InnoCare Pharma | 1,176 |
| Duality Biotherapeutics | 231 |
| RemeGen | 3,048 |
| Keymed Biosciences | 1,625 |
Shanghai Junshi Biosciences News
- 8 days ago - Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026 - GlobeNewsWire
- 6 weeks ago - Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 weeks ago - Junshi Biosciences Announces NMPA Acceptance of New Drug Applications for Toripalimab Injection (Subcutaneous) Across 12 Indications - GlobeNewsWire
- 2 months ago - Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb) - PRNewsWire
- 2 months ago - Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor) - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis - GlobeNewsWire
- 5 months ago - Junshi Biosciences Announces Primary Endpoints Met in JS001sc's Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC - GlobeNewsWire
- 6 months ago - Junshi Biosciences Announces FDA's Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients - GlobeNewsWire